A patient with primary hypercholesterolemia is taking an HMG-CoA reductase inhibitor.All of the patient's baseline LFTs were normal.At a 6-month follow-up visit,the patient reports occasional headache.A lipid profile reveals a decrease of 20% in the patient's LDL cholesterol.The NP should:

Question

Quizplus · Accepted Answer

LFTs should be performed at baseline,12 weeks after initiation of therapy,and only periodically thereafter.Headaches are common side effects,but do not raise concern about hepatotoxicity.CK-MM tests are indicated if patients report muscle pain or weakness.It is not necessary to decrease the medication.

A Patient with Primary Hypercholesterolemia Is Taking an HMG-CoA Reductase